Related Experiment Video
Updated: May 5, 2026
Measuring Composition of CD95 Death-Inducing Signaling Complex and Processing of Procaspase-8 in this Complex
Published on: August 2, 2021
Cytotoxicity of ICD-85 NPs on Human Cervical Carcinoma HeLa Cells through Caspase-8 Mediated Pathway
Saeed Moradhaseli1, Abbas Zare Mirakabadi, Ali Sarzaeem
1Department of Biochemistry, Faculty of Basic Sciences, Payame Noor University, Tehran, Iran.
Abstract:
The biological application of nanoparticles (NPs) is a rapidly developing area of nanotechnology that raises new possibilities in the treatment of human cancers. The cytotoxicity was evaluated by MTT and LDH assays. The apoptotic effect of free ICD-85 and ICD-85 NPs on HeLa cells was assessed using caspase-8 colorimetric assay. The MTT assay showed that ICD-85 NPs could enhance the in-vitro cytotoxicity against HeLa cells compared to the free ICD-85. The IC50 value at 72 h was reduced from 25 ± 2.9 μg/mL for free ICD-85 to 15.5 ± 2.4 μg/mL for ICD-85 NPs. However, LDH assay demonstrated that ICD-85 has dose-dependent cytotoxicity on HeLa cells while ICD-85 NPs exhibited weaker cytotoxicity on same cells. The results also indicate that ICD-85-induced apoptosis on HeLa cells is associated with the activation of caspase-8. Moreover, caspase-8 assay analysis demonstrated that the ICD- 85 NPs induced a higher apoptotic rate in HeLa cells compared to free ICD-85. Our results demonstrated that the encapsulation of ICD-85 enhances its anti-proliferative effects. Taken together, these results suggest that the delivery of ICD-85 in nanoparticles may be a promising approach for the treatment of the cancer.
Insights
Nanoparticles (NPs) carrying ICD-85 show enhanced anti-cancer effects against HeLa cells, increasing cytotoxicity and apoptosis. This suggests NPs are a promising delivery system for cancer treatment.
Area of Science:
- Nanotechnology
- Cancer Biology
- Drug Delivery
Background:
- Nanoparticles (NPs) offer novel therapeutic strategies for human cancers.
- ICD-85 is an agent with potential anti-cancer properties.
Purpose of the Study:
- To evaluate the in-vitro cytotoxicity and apoptotic effects of free ICD-85 and ICD-85 encapsulated in nanoparticles (ICD-85 NPs) on HeLa cells.
- To assess the potential of ICD-85 NPs as a cancer treatment delivery system.
Main Methods:
- Cytotoxicity was assessed using MTT and Lactate Dehydrogenase (LDH) assays.
- Apoptosis induction was evaluated via caspase-8 colorimetric assay.
- Half-maximal inhibitory concentration (IC50) values were determined.
Main Results:
- ICD-85 NPs demonstrated significantly enhanced in-vitro cytotoxicity against HeLa cells compared to free ICD-85, with a lower IC50 value (15.5 ± 2.4 μg/mL vs. 25 ± 2.9 μg/mL at 72 h).
- While free ICD-85 showed dose-dependent cytotoxicity, ICD-85 NPs exhibited weaker cytotoxicity in the LDH assay.
- ICD-85 NPs induced a higher apoptotic rate in HeLa cells through caspase-8 activation compared to free ICD-85.
Conclusions:
- Encapsulation of ICD-85 into nanoparticles enhances its anti-proliferative effects and augments apoptosis induction in cancer cells.
- Delivery of ICD-85 via nanoparticles represents a promising approach for cancer therapy.
More Related Videos
Related Concept Videos
01:24Caspases
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:17The Extrinsic Apoptotic Pathway
01:31The Intrinsic Apoptotic Pathway
01:22Cellular Injury V: Apoptosis and Autophagy
01:28Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...